Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2008 1
2010 3
2011 2
2012 4
2013 4
2014 4
2015 1
2016 2
2017 3
2018 3
2019 4
2020 9
2021 6
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C. Shen JZ, et al. Among authors: rantala j. Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23. Cell. 2021. PMID: 33357448 Free PMC article.
FBXL12 degrades FANCD2 to regulate replication recovery and promote cancer cell survival under conditions of replication stress.
Brunner A, Li Q, Fisicaro S, Kourtesakis A, Viiliäinen J, Johansson HJ, Pandey V, Mayank AK, Lehtiö J, Wohlschlegel JA, Spruck C, Rantala JK, Orre LM, Sangfelt O. Brunner A, et al. Among authors: rantala jk. Mol Cell. 2023 Oct 19;83(20):3720-3739.e8. doi: 10.1016/j.molcel.2023.07.026. Epub 2023 Aug 16. Mol Cell. 2023. PMID: 37591242 Free article.
A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.
Shen JZ, Qiu Z, Wu Q, Zhang G, Harris R, Sun D, Rantala J, Barshop WD, Zhao L, Lv D, Won KA, Wohlschlegel J, Sangfelt O, Laman H, Rich JN, Spruck C. Shen JZ, et al. Among authors: rantala j. Mol Cell. 2022 Mar 17;82(6):1123-1139.e8. doi: 10.1016/j.molcel.2022.01.022. Epub 2022 Feb 18. Mol Cell. 2022. PMID: 35182481 Free PMC article.
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
Kryza T, Khan T, Lovell S, Harrington BS, Yin J, Porazinski S, Pajic M, Koistinen H, Rantala JK, Dreyer T, Magdolen V, Reuning U, He Y, Tate EW, Hooper JD. Kryza T, et al. Among authors: rantala jk. Nat Chem Biol. 2021 Jul;17(7):776-783. doi: 10.1038/s41589-021-00783-w. Epub 2021 Apr 15. Nat Chem Biol. 2021. PMID: 33859413
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients.
Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ, Collis SJ, Wells G. Gagg H, et al. Among authors: rantala j. F1000Res. 2024 Mar 11;12:954. doi: 10.12688/f1000research.135809.1. eCollection 2023. F1000Res. 2024. PMID: 37799492 Free PMC article.
Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J, Qiao X, Weltner J, Rantala JK, Carpén T, Hagström J, Mäkitie A, Leivo I, Ruuskanen M, Söderlund J, Rintala M, Hietanen S, Irjala H, Minn H, Westermarck J, Ventelä S. Routila J, et al. Among authors: rantala jk. Oral Oncol. 2022 Apr;127:105772. doi: 10.1016/j.oraloncology.2022.105772. Epub 2022 Mar 1. Oral Oncol. 2022. PMID: 35245886 Free article.
52 results